All In Biotech

Drug Trial Radar · NCT04361032

Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia

Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia. Multicentric, Comparative, Randomized Study

Last checked: Nov 19, 2026Latest source record: Aug 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 260 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

260

Planned (sponsor's estimate)

Start

Sep 4, 2020

Primary completion

Sep 4, 2020

Study completion Oct 4, 2020

Sponsor

Lead sponsor
Abderrahmane Mami HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Eshmoun Clinical Research Center; Datametrix
First posted
Apr 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, associated with standards treatments in COVID-19 (+) patients, Hospitalized In Intensive care in Tunisia. Multicentric, comparative, randomized study.

Conditions

  • COVID19
  • Intensive Care Unit

Interventions

  • Tocilizumab InjectionDrug

    Tocilizumab (LOC) (8mg/ kg per day) (1 injection per infusion). Only on the 1st day (D0)

  • DeferoxamineDrug

    Deferoxamine (Desferal 500 mg, powder, and solvent for IV solution for injection)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the mortality rateTime frame: 90 day

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Eshmoun Clinical Research Centre/ Hôpital Abderrahmane Mami-Ariana

    Aryanah, Tunisia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.